Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
Clinical trial NCT04695925 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04695925
- Sponsor
- Li Zhang, MD
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-29
- Primary completion
- 2025-11-01
- Enrollment
- 294
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.